Sarcoidosis, susceptibility to, 1

Summary

Sarcoidosis, susceptibility to, 1 (MONDO:0008399) is a disease with 1 cohort gene and 188 clinical trials. Top therapeutic interventions include corticotropin, cravacitinib, and bosentan.

At a glance

• Cohort genes: 1
• ClinVar variants: 1
• Clinical trials: 188

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	sarcoidosis, susceptibility to, 1
Mondo ID	MONDO:0008399
OMIM	181000
UMLS	C2697310
MedGen	394568
Is cancer (heuristic)	no

Also known as: HLA-DRB1 sarcoidosis · sarcoidosis · sarcoidosis caused by mutation in HLA-DRB1 · sarcoidosis, susceptibility to, 1 · sarcoidosis, susceptibility to, type 1 · SS1

Data availability: 1 ClinVar variant · 12 cell lines.

Disease family

Classification path: disease susceptibility › inherited disease susceptibility › sarcoidosis, susceptibility to, 1

Related subtypes (283): microvascular complications of diabetes, susceptibility, Mycobacterium tuberculosis, susceptibility, bacteremia, susceptibility, pregnancy loss, recurrent, susceptibility, autoimmune thyroid disease, susceptibility to, susceptibility to HIV infection, appendicitis, proneness to, atherosclerosis susceptibility, multiple sclerosis, susceptibility to, dyslexia, susceptibility to, 1, endometriosis, susceptibility to, 1, osteoarthritis susceptibility 2, essential hypertension, genetic, osteoarthritis susceptibility 1, otitis media, susceptibility to, pelvic organ prolapse, susceptibility to, pulmonary edema of mountaineers, susceptibility to, strabismus, susceptibility to, thyrotoxic periodic paralysis, susceptibility to, 1, predisposition to invasive fungal disease due to CARD9 deficiency, celiac disease, susceptibility to, 1, hemolytic uremic syndrome, atypical, susceptibility to, 1, hypervitaminosis a, susceptibility to, kuru, susceptibility to, leprosy, susceptibility to, 3, nonarteritic anterior ischemic optic neuropathy, susceptibility to, diabetes mellitus, insulin-dependent, X-linked, susceptibility to, coronary heart disease, susceptibility to, 3, dyslexia, susceptibility to, 9, systemic lupus erythematosus, susceptibility to, 15, Leber optic atrophy, susceptibility to, dyslexia, susceptibility to, 2, Helicobacter pylori infection, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 1, inherited susceptibility to asthma, renal dysplasia, cystic, susceptibility to, systemic lupus erythematosus, susceptibility to, 1, leishmaniasis, tegumentary, susceptibility to, xanthomatosis, susceptibility to, hyperlipidemia, combined, 1, urinary tract infections, recurrent, susceptibility to, hypertension, essential, susceptibility to, 1, hepatic fibrosis, severe, susceptibility to, due to Schistosoma mansoni infection, dyslexia, susceptibility to, 3, Ascaris lumbricoides infection, susceptibility to, hypertension, essential, susceptibility to, 2, epilepsy, idiopathic generalized, susceptibility to, 7, systemic lupus erythematosus, susceptibility to, 2, systemic lupus erythematosus, susceptibility to, 3, nephrolithiasis, uric acid, susceptibility to, atrioventricular septal defect, susceptibility to, 2, vitiligo-associated multiple autoimmune disease susceptibility 1, polysubstance abuse, susceptibility to, dyslexia, susceptibility to, 6, glaucoma, normal tension, susceptibility to, anorexia nervosa, susceptibility to, 1, stroke, susceptibility to, 1, dyslexia, susceptibility to, 5, epilepsy, idiopathic generalized, susceptibility to, 2, familial meningioma, celiac disease, susceptibility to, 5, systemic lupus erythematosus with hemolytic anemia, susceptibility to, 1, hypertension, essential, susceptibility to, 3, coronary heart disease, susceptibility to, 1, bulimia nervosa, susceptibility to, 1, leprosy, susceptibility to, 2, epilepsy, idiopathic generalized, susceptibility to, 9, Parkinson disease 11, autosomal dominant, susceptibility to, focal segmental glomerulosclerosis 3, susceptibility to, autoimmune disease, susceptibility to, 1, osteoarthritis susceptibility 3, systemic lupus erythematosus with nephritis, susceptibility to, 1, systemic lupus erythematosus with nephritis, susceptibility to, 2, systemic lupus erythematosus with nephritis, susceptibility to, 3, coronary heart disease, susceptibility to, 2, coronary heart disease, susceptibility to, 4, autoimmune disease, susceptibility to, 2, autoimmune disease, susceptibility to, 3, systemic lupus erythematosus, susceptibility to, 4, myocardial infarction, susceptibility to, major depressive disorder 1, legionnaire disease, susceptibility to, myocardial infarction, susceptibility to, 2, major depressive disorder 2, hypertension, essential, susceptibility to, 4, epilepsy, idiopathic generalized, susceptibility to, 3, myoclonic epilepsy, juvenile, susceptibility to, 3, orofacial cleft 6, susceptibility to, coronary heart disease, susceptibility to, 5, attention deficit-hyperactivity disorder, susceptibility to, 1, attention deficit-hyperactivity disorder, susceptibility to, 2, attention deficit-hyperactivity disorder, susceptibility to, 3, attention deficit-hyperactivity disorder, susceptibility to, 4, Alzheimer disease 9, susceptibility to respiratory infections associated with CD8alpha chain mutation, dyslexia, susceptibility to, 8, autoimmune disease, susceptibility to, 4, hepatitis C virus, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 4, celiac disease, susceptibility to, 4, celiac disease, susceptibility to, 2, celiac disease, susceptibility to, 3, leprosy, susceptibility to, 1, systemic lupus erythematosus, susceptibility to, 5, systemic lupus erythematosus, susceptibility to, 6, opioid dependence, susceptibility to, 1, systemic lupus erythematosus, susceptibility to, 7, systemic lupus erythematosus, susceptibility to, 8, hypertension, essential, susceptibility to, 5, hypertension, essential, susceptibility to, 6, Parkinson disease 13, autosomal dominant, susceptibility to, West Nile virus, susceptibility to, hepatitis B virus, susceptibility to, Buruli ulcer, susceptibility to, osteoarthritis susceptibility 4, systemic lupus erythematosus, susceptibility to, 9, coronary heart disease, susceptibility to, 7, hypertension, essential, susceptibility to, 7, leprosy, susceptibility to, 4, hypertension, essential, susceptibility to, 8, epilepsy, idiopathic generalized, susceptibility to, 13, coronary heart disease, susceptibility to, 8, myoclonic epilepsy, juvenile, susceptibility to, 4, susceptibility to visceral leishmaniasis, 2, susceptibility to visceral leishmaniasis, 3, celiac disease, susceptibility to, 6, epilepsy, idiopathic generalized, susceptibility to, 5, epilepsy, childhood absence, susceptibility to, 6, celiac disease, susceptibility to, 7, celiac disease, susceptibility to, 8, celiac disease, susceptibility to, 9, celiac disease, susceptibility to, 10, celiac disease, susceptibility to, 11, celiac disease, susceptibility to, 12, celiac disease, susceptibility to, 13, coronary heart disease, susceptibility to, 9, systemic lupus erythematosus, susceptibility to, 10, systemic lupus erythematosus, susceptibility to, 11, systemic lupus erythematosus, susceptibility to, 12, epilepsy, childhood absence, susceptibility to, 5, attention deficit-hyperactivity disorder, susceptibility to, 5, attention deficit-hyperactivity disorder, susceptibility to, 6, systemic lupus erythematosus, susceptibility to, 13, sarcoidosis, susceptibility to, 2, sarcoidosis, susceptibility to, 3, osteoarthritis susceptibility 5, osteoarthritis susceptibility 6, focal segmental glomerulosclerosis 4, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 8, herpes simplex encephalitis, susceptibility to, 2, attention deficit-hyperactivity disorder, susceptibility to, 7, epilepsy, idiopathic generalized, susceptibility to, 10, pelvic organ prolapse, susceptibility to, 2, systemic lupus erythematosus, susceptibility to, 14, leprosy, susceptibility to, 5, thyrotoxic periodic paralysis, susceptibility to, 2, hearing loss, cisplatin-induced, susceptibility to, susceptibility to mononeuropathy of the median nerve, mild, fatty liver disease, nonalcoholic, susceptibility to, 2, leprosy, susceptibility to, 6, autoimmune disease, susceptibility to, 6, Parkinson disease 5, autosomal dominant, susceptibility to, aspergillosis, susceptibility to, sick sinus syndrome 3, susceptibility to, Parkinson disease 18, autosomal dominant, susceptibility to, epilepsy, juvenile myoclonic, susceptibility to, 9, dengue virus, susceptibility to, coronary heart disease, susceptibility to, 6, podoconiosis, susceptibility to, peripartum cardiomyopathy, susceptibility to, influenza, severe, susceptibility to, thyrotoxic periodic paralysis, susceptibility to, 3, human herpesvirus 8, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 12, herpes simplex encephalitis, susceptibility to, 3, herpes simplex encephalitis, susceptibility to, 4, pulmonary hypertension, neonatal, susceptibility to, craniosynostosis 5, susceptibility to, melioidosis, susceptibility to, chronic mountain sickness, susceptibility to, herpes simplex encephalitis, susceptibility to, 7, epilepsy, idiopathic generalized, susceptibility to, 14, hereditary neoplastic syndrome, autosomal recessive Mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency, autosomal recessive Mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency, susceptibility to localized juvenile periodontitis, inherited susceptibility to mycobacterial diseases, neural tube defects, susceptibility to, multiple system atrophy 1, susceptibility to, nephrolithiasis susceptibility caused by SLC26A1, myoclonic epilepsy, juvenile, susceptibility to, 1, epilepsy, childhood absence, susceptibility to, 1, autism, susceptiblity to, susceptibility to visceral leishmaniasis, 1, malaria, susceptibility to, spondyloarthropathy, susceptibility to, herpes simplex encephalitis, susceptibility to, 1, epilepsy, idiopathic generalized, susceptibility to, 18, epilepsy, idiopathic generalized, susceptibility to, 15, hepatitis, fulminant viral, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 16, autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial jak1 deficiency, aortic aneurysm, familial thoracic 11, susceptibility to, craniosynostosis 7, amyotrophic lateral sclerosis, susceptibility to, 24, amyotrophic lateral sclerosis, susceptibility to, 25, epilepsy, juvenile myoclonic, susceptibility to, 10, susceptibility to angioedema induced by ACE inhibitors, epidermodysplasia verruciformis, susceptibility to, exfoliation syndrome, susceptibility to, basal cell carcinoma, susceptibility to, graft-versus-host disease, susceptibility to, narcolepsy, susceptibility to, pulmonary disease, chronic obstructive, susceptibility to, restless legs syndrome, susceptibility to, psoriasis, susceptibility to, age related macular degeneration, susceptibility to, allergic rhinitis, susceptibility to, dermatitis, atopic, susceptibility to, Hirschsprung disease, susceptibility to, diabetes mellitus, ketosis-prone, schizophrenia, susceptibility to, radioulnar synostosis, nonsyndromic, susceptibility to, lumbar disk herniation, susceptibility to, lumbar disk degeneration, susceptibility to, psoriatic arthritis, susceptibility to, migraine with or without aura, susceptibility to, Alzheimer disease, susceptibility to, mitochondrial, Asperger syndrome, susceptibility to, tobacco addiction, susceptibility to, lipodystrophy, partial, acquired, susceptibility to, Graves disease, susceptibility to, 1, epilepsy, idiopathic generalized, susceptibility to, 17, breast-ovarian cancer, familial, susceptibility to, blepharospasm, benign essential, susceptibility to, hemorrhage, intracerebral, susceptibility to, IgA nephropathy, susceptibility to, hemolytic uremic syndrome, atypical, susceptibility to, 7, vitiligo-associated multiple autoimmune disease susceptibility 6, delayed sleep phase syndrome, susceptibility to, encephalitis, acute, infection-induced, susceptibility to, malignant hyperthermia, susceptibility to, multicentric Castleman disease, susceptibility to, pelvic organ prolapse, susceptibility to, 1, amyotrophic lateral sclerosis, susceptibility to, 13, Graves disease, susceptibility to, X-linked 2, autoimmune thyroid disease, susceptibility to, 5, atrioventricular septal defect, susceptibility to, 1, epilepsy, juvenile myoclonic, susceptibility to, 6, autoimmune disease, susceptibility to, 5, epilepsy, idiopathic generalized, susceptibility to, 6, seasonal affective disorder, susceptibility to, ventricular fibrillation during myocardial infarction, susceptibility to, UV-induced skin damage, susceptibility to, antisocial behavior, susceptibility to, aplastic anemia, susceptibility to, cardiomyopathy, familial hypertrophic, 4, susceptibility to, cirrhosis, noncryptogenic, susceptibility to, coronary artery disease, severe, susceptibility to, dengue fever, susceptibility to, dengue hemorrhagic fever, susceptibility to, dengue shock syndrome, susceptibility to, dyslexia, susceptibility to, 4, dyslexia, susceptibility to, 7, efavirenz central nervous system toxicity, susceptibility to, obesity, susceptibility to, bleeding disorder, platelet-type, 13, susceptibility to, Schistosoma mansoni infection, susceptibility/resistance to, Parkinson disease 24, autosomal dominant, susceptibility to, iron overload, susceptibility to, hydrocephalus, congenital, 5, susceptibility to, hearing loss, noise-induced, susceptibility to, hyperemesis gravidarum, susceptibility to, Parkinson disease 26, autosomal dominant, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 19, polycystic kidney disease 9, susceptibility to, rhabdomyolysis, susceptibility to, scoliosis, isolated, susceptibility to, dystonia 38, susceptibility to, gallbladder disease 4, epilepsy, juvenile absence, susceptibility to, GBA1-related Parkinson disease, susceptibility, SH2B3-related immune system disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 risk factor

ClinVar	Variant (HGVS)	Gene	Classification	Review
14905	HLA-DRB1, HLA-DRB1*1101	HLA-DRB1	risk factor	no assertion criteria provided

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 14 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
HLA-DRB1	Orphanet:2073	Narcolepsy type 1
HLA-DRB1	Orphanet:220393	Diffuse cutaneous systemic sclerosis
HLA-DRB1	Orphanet:220402	Limited cutaneous systemic sclerosis
HLA-DRB1	Orphanet:220407	Limited systemic sclerosis
HLA-DRB1	Orphanet:3437	Vogt-Koyanagi-Harada disease
HLA-DRB1	Orphanet:397	Giant cell arteritis
HLA-DRB1	Orphanet:477738	Pediatric multiple sclerosis
HLA-DRB1	Orphanet:536	Systemic lupus erythematosus
HLA-DRB1	Orphanet:545	Follicular lymphoma
HLA-DRB1	Orphanet:703	Bullous pemphigoid
HLA-DRB1	Orphanet:747	Autoimmune pulmonary alveolar proteinosis
HLA-DRB1	Orphanet:797	Sarcoidosis
HLA-DRB1	Orphanet:83465	Narcolepsy type 2
HLA-DRB1	Orphanet:85414	Systemic-onset juvenile idiopathic arthritis

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
HLA-DRB1	HGNC:4948	ENSG00000196126	P01911	HLA class II histocompatibility antigen, DRB1 beta chain	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
HLA-DRB1	HLA class II histocompatibility antigen, DRB1 beta chain	A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	1	29.2×	0.034

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
HLA-DRB1	Antibody/Immunoglobulin	yes		MHC_II_b_N, Ig/MHC_CS, Ig_C1-set

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
granulocyte	1
right lung	1
vermiform appendix	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
HLA-DRB1	131	tissue_specific	marker	vermiform appendix, granulocyte, right lung

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
HLA-DRB1	3,448

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
HLA-DRB1	P01911	108

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 7. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Translocation of ZAP-70 to Immunological synapse	1	634.4×	0.004	HLA-DRB1
Phosphorylation of CD3 and TCR zeta chains	1	543.8×	0.004	HLA-DRB1
Co-inhibition by PD-1	1	519.1×	0.004	HLA-DRB1
Generation of second messenger molecules	1	346.1×	0.005	HLA-DRB1
Downstream TCR signaling	1	128.3×	0.009	HLA-DRB1
Interferon gamma signaling	1	125.5×	0.009	HLA-DRB1
MHC class II antigen presentation	1	89.2×	0.011	HLA-DRB1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of interleukin-4 production	1	16852.0×	0.001	HLA-DRB1
antigen processing and presentation of endogenous peptide antigen via MHC class II	1	8426.0×	0.001	HLA-DRB1
regulation of interleukin-10 production	1	8426.0×	0.001	HLA-DRB1
myeloid dendritic cell antigen processing and presentation	1	5617.3×	0.001	HLA-DRB1
regulation of T-helper cell differentiation	1	4213.0×	0.001	HLA-DRB1
positive regulation of CD4-positive, alpha-beta T cell activation	1	4213.0×	0.001	HLA-DRB1
positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation	1	3370.4×	0.001	HLA-DRB1
positive regulation of T cell mediated immune response to tumor cell	1	2407.4×	0.002	HLA-DRB1
T-helper 1 type immune response	1	1872.4×	0.002	HLA-DRB1
positive regulation of memory T cell differentiation	1	1872.4×	0.002	HLA-DRB1
positive regulation of monocyte differentiation	1	1532.0×	0.002	HLA-DRB1
detection of bacterium	1	1404.3×	0.002	HLA-DRB1
peptide antigen assembly with MHC class II protein complex	1	1053.2×	0.002	HLA-DRB1
inflammatory response to antigenic stimulus	1	936.2×	0.002	HLA-DRB1
protein tetramerization	1	624.1×	0.003	HLA-DRB1
negative regulation of inflammatory response to antigenic stimulus	1	601.9×	0.003	HLA-DRB1
antigen processing and presentation of exogenous peptide antigen via MHC class II	1	543.6×	0.003	HLA-DRB1
positive regulation of T cell mediated cytotoxicity	1	510.7×	0.003	HLA-DRB1
positive regulation of immune response	1	481.5×	0.003	HLA-DRB1
macrophage differentiation	1	468.1×	0.003	HLA-DRB1
positive regulation of T cell activation	1	443.5×	0.003	HLA-DRB1
negative regulation of type II interferon production	1	383.0×	0.003	HLA-DRB1
positive regulation of insulin secretion involved in cellular response to glucose stimulus	1	374.5×	0.003	HLA-DRB1
negative regulation of T cell proliferation	1	330.4×	0.004	HLA-DRB1
humoral immune response	1	280.9×	0.004	HLA-DRB1
epidermis development	1	210.7×	0.005	HLA-DRB1
T cell receptor signaling pathway	1	151.8×	0.007	HLA-DRB1
immune response	1	47.1×	0.022	HLA-DRB1
signal transduction	1	16.1×	0.062	HLA-DRB1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
HLA-DRB1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
HLA-DRB1	17	Binding:17

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	HLA-DRB1
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
HLA-DRB1	17	—

Clinical trials & evidence

Clinical trials

Clinical trials: 188.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	136
PHASE2	17
PHASE4	14
PHASE2/PHASE3	8
PHASE3	7
PHASE1/PHASE2	3
EARLY_PHASE1	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03621553	PHASE4	RECRUITING	Vitamin D Homeostasis in Sarcoidosis
NCT06654934	PHASE4	NOT_YET_RECRUITING	Prednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis
NCT00361387	PHASE4	COMPLETED	Use of Focalin for Fatigue in Sarcoidosis
NCT00403650	PHASE4	COMPLETED	Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
NCT00747461	PHASE4	TERMINATED	Interventional Cryotherapy for the Eradication of Benign Airway Disease (ICE the BAD)
NCT01210677	PHASE4	WITHDRAWN	Cardiac Sarcoidosis Response To Steroids Trial
NCT01658280	PHASE4	COMPLETED	Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies
NCT01830959	PHASE4	UNKNOWN	Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)
NCT02188017	PHASE4	UNKNOWN	Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)
NCT02246023	PHASE4	COMPLETED	Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy
NCT02523092	PHASE4	TERMINATED	Use of CXCL9 as a Biomarker of Acthar Efficacy
NCT02625558	PHASE4	UNKNOWN	Riociguat for Sarcoidosis Associated Pulmonary Hypertension
NCT02920710	PHASE4	WITHDRAWN	ACTHAR Therapy for Central Nervous System Sarcoidosis
NCT03265405	PHASE4	COMPLETED	Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis
NCT03593759	PHASE3	RECRUITING	Cardiac Sarcoidosis Randomized Trial
NCT05689879	PHASE3	ACTIVE_NOT_RECRUITING	Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis
NCT00073437	PHASE3	COMPLETED	A Study of Infliximab in Patients With Sarcoidosis
NCT00305552	PHASE3	COMPLETED	SARCOTHAL. Thalidomide in Skin Sarcoidosis
NCT00555347	PHASE2/PHASE3	COMPLETED	Use of Armodafinil for Fatigue in Sarcoidosis
NCT00581607	PHASE2/PHASE3	COMPLETED	Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
NCT00794274	PHASE2/PHASE3	COMPLETED	The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis
NCT00851929	PHASE2/PHASE3	COMPLETED	Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
NCT00872612	PHASE3	COMPLETED	Trial for the Diagnosis of Sarcoidosis
NCT01687517	PHASE3	COMPLETED	Efficacy and Safety of Influenza Vaccine During Sarcoidosis
NCT01920919	PHASE3	UNKNOWN	Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis
NCT01955824	PHASE2/PHASE3	COMPLETED	A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy
NCT02155803	PHASE2/PHASE3	UNKNOWN	ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study
NCT02348905	PHASE2/PHASE3	UNKNOWN	ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial
NCT02875756	PHASE2/PHASE3	COMPLETED	Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis
NCT05458492	PHASE2	NOT_YET_RECRUITING	Sirolimus in Cutaneous Sarcoidosis
NCT00000596	PHASE2	COMPLETED	Diffuse Fibrotic Lung Disease
NCT00274352	PHASE2	COMPLETED	A Study of Adalimumab to Treat Sarcoidosis of the Skin
NCT00282438	PHASE1/PHASE2	TERMINATED	Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
NCT00311246	PHASE2	TERMINATED	Trial of Adalimumab in Progressive Sarcoidosis
NCT00690911	PHASE2	WITHDRAWN	Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis
NCT00731757	PHASE2	WITHDRAWN	Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis
NCT00739960	PHASE2	TERMINATED	Safety Study of Abatacept to Treat Refractory Sarcoidosis
NCT00855205	PHASE2	COMPLETED	Rituximab for Pulmonary Sarcoidosis
NCT00926627	PHASE2	TERMINATED	Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis
NCT00955279	PHASE2	COMPLETED	A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CORTICOTROPIN	4	3
CRAVACITINIB	4	3
BOSENTAN	4	2
ABATACEPT	4	1
ABROCITINIB	4	1
AMBRISENTAN	4	1
ARMODAFINIL	4	1
DAPSONE	4	1
DIMERCAPROL	4	1
ERGOCALCIFEROL	4	1
GOLIMUMAB	4	1
ILOPROST	4	1
INFLIXIMAB	4	1
OXYGEN	4	1
PREDNISONE	4	1
RIOCIGUAT	4	1
ROFLUMILAST	4	1
SARILUMAB	4	1
THALIDOMIDE	4	1
TREPROSTINIL	4	1
USTEKINUMAB	4	1
BARDOXOLONE METHYL	3	1
QUERCETIN	3	1
RUBIDIUM	3	1
TRANILAST	3	1
LUFENURON	2	1
CHEMBL15720	0	2
CHEMBL50241	0	1
CHEMBL426123	0	1
CHEMBL302753	0	1